Raymond James Financial Inc. acquired a new position in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 924,943 shares of the medical research company's stock, valued at approximately $146,419,000. Raymond James Financial Inc. owned approximately 0.70% of Natera at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also modified their holdings of the company. Wellington Management Group LLP boosted its holdings in Natera by 205.4% during the third quarter. Wellington Management Group LLP now owns 2,800,263 shares of the medical research company's stock valued at $355,493,000 after purchasing an additional 1,883,481 shares in the last quarter. PointState Capital LP boosted its stake in Natera by 112.0% in the 3rd quarter. PointState Capital LP now owns 782,538 shares of the medical research company's stock valued at $99,343,000 after buying an additional 413,468 shares in the last quarter. Franklin Resources Inc. boosted its stake in Natera by 42.6% in the 3rd quarter. Franklin Resources Inc. now owns 1,099,335 shares of the medical research company's stock valued at $144,958,000 after buying an additional 328,375 shares in the last quarter. ARK Investment Management LLC grew its position in Natera by 65.6% in the third quarter. ARK Investment Management LLC now owns 687,703 shares of the medical research company's stock valued at $87,304,000 after acquiring an additional 272,361 shares during the period. Finally, Maverick Capital Ltd. lifted its holdings in shares of Natera by 25.2% during the third quarter. Maverick Capital Ltd. now owns 1,340,045 shares of the medical research company's stock valued at $170,119,000 after acquiring an additional 269,706 shares during the period. 99.90% of the stock is currently owned by institutional investors.
Insider Transactions at Natera
In other Natera news, insider John Fesko sold 669 shares of Natera stock in a transaction on Monday, December 23rd. The shares were sold at an average price of $159.60, for a total value of $106,772.40. Following the sale, the insider now directly owns 114,142 shares in the company, valued at approximately $18,217,063.20. The trade was a 0.58 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Michael Burkes Brophy sold 946 shares of the company's stock in a transaction dated Friday, January 24th. The stock was sold at an average price of $171.98, for a total value of $162,693.08. Following the sale, the chief financial officer now owns 109,474 shares in the company, valued at $18,827,338.52. The trade was a 0.86 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 294,946 shares of company stock valued at $47,212,702 over the last three months. Company insiders own 7.60% of the company's stock.
Analysts Set New Price Targets
NTRA has been the subject of a number of recent analyst reports. Barclays began coverage on shares of Natera in a research report on Thursday, January 23rd. They set an "overweight" rating and a $200.00 target price for the company. StockNews.com raised Natera from a "sell" rating to a "hold" rating in a report on Tuesday. JPMorgan Chase & Co. raised their price target on Natera from $160.00 to $200.00 and gave the company an "overweight" rating in a report on Friday, December 13th. Sanford C. Bernstein raised their target price on Natera from $160.00 to $200.00 and gave the company an "outperform" rating in a research note on Friday, January 10th. Finally, Robert W. Baird upped their price target on shares of Natera from $183.00 to $188.00 and gave the stock an "outperform" rating in a research report on Friday, February 28th. One equities research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $173.56.
Read Our Latest Stock Analysis on Natera
Natera Trading Up 5.6 %
Natera stock traded up $7.39 during mid-day trading on Tuesday, hitting $140.02. 2,219,491 shares of the company's stock were exchanged, compared to its average volume of 1,338,070. Natera, Inc. has a fifty-two week low of $83.13 and a fifty-two week high of $183.00. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. The firm has a market capitalization of $18.93 billion, a P/E ratio of -79.56 and a beta of 1.80. The company's 50 day simple moving average is $165.10 and its 200-day simple moving average is $148.16.
Natera (NASDAQ:NTRA - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The medical research company reported ($0.41) earnings per share for the quarter, beating the consensus estimate of ($0.42) by $0.01. The business had revenue of $476.10 million for the quarter, compared to analysts' expectations of $447.91 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. On average, equities analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current year.
About Natera
(
Free Report)
Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.
Read More
Before you consider Natera, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Natera wasn't on the list.
While Natera currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
